Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells.
North K, Benbarche S, Liu B, Pangallo J, Chen S, Stahl M, Bewersdorf JP, Stanley RF, Erickson C, Cho H, Pineda JMB, Thomas JD, Polaski JT, Belleville AE, Gabel AM, Udy DB, Humbert O, Kiem HP, Abdel-Wahab O, Bradley RK.
North K, et al. Among authors: polaski jt.
Nat Biotechnol. 2022 Jul;40(7):1103-1113. doi: 10.1038/s41587-022-01224-2. Epub 2022 Mar 3.
Nat Biotechnol. 2022.
PMID: 35241838
Free PMC article.